|Bid||4.1200 x 21500|
|Ask||0.0000 x 4000|
|Day's Range||3.9200 - 4.1800|
|52 Week Range||2.0900 - 13.7100|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.57|
Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Akebia Therapeutics, Inc. ("Akebia" or "the Company") (NASDAQ: AKBA) who formerly held shares of Keryx Biopharmaceuticals, Inc. (KERX) for violations of the securities laws.If you are a shareholder, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, ...
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders should be happy to see the share price up 10% in the last month...
Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Under the terms of the agreement, Akebia will be solely responsible for the research, development, and commercialization of praliciguat globally. Cyclerion is eligible to receive up to $225 million in pre-commercial milestones, including up to $15 million in the first 18 months. Total potential futu